Efficacy of Botulinum Toxin in Temporomandibular Disorders

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

March 30, 2021

Study Completion Date

July 30, 2021

Conditions
Temporomandibular Joint Disorder Bilateral
Interventions
DRUG

Botulinum toxin type A injection

The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.

Trial Locations (1)

37007

Clinica Odontológica de la Universidad de Salamanca, Salamanca

All Listed Sponsors
lead

University of Salamanca

OTHER

NCT05651256 - Efficacy of Botulinum Toxin in Temporomandibular Disorders | Biotech Hunter | Biotech Hunter